Full Press Release Details
Files 2013 Annual Report on Form 20-F
April 16, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that
focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013
Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16,
2014. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations
Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests
for a hard copy of the 2013 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's
website by submitting complete mailing details on the request form.
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization
of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines. The Company recently concluded
the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease) and filed new drug application with China
Food & Drug Administration. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine,
Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company
is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing
a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has
also been granted a license to commercialize seasonal flu vaccine in Mexico.
announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the
U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Among other things, the business outlook and quotations from
management in this press release contain forward-looking statements. Statements that are not historical facts, including statements
about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and
uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking
statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable
+86-10-8279-9659/9696